Economic Evaluation of Third-Line Treatment with Alemtuzumab for Chronic Lymphocytic Leukaemia

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.27, Iss.11, 2007-01, pp. : 755-764

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic assessment on the management of chronic lymphocytic leukaemia

By Goor Kim M Schaafsma M Ronald Huijgens Peter C van Agthoven Michel

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 7, 2005-06 ,pp. : 1179-1189

Informa Healthcare

Access to resources Recommend Favorite

New Directions in the Diagnosis and Treatment of Chronic Lymphocytic Leukaemia

By Schriever F. Huhn D.

Drugs, Vol. 63, Iss. 10, 2003-01 ,pp. : 953-969

Adis International

Access to resources Recommend Favorite

Management of Chronic Lymphocytic Leukaemia

By Kalil N. Cheson B.D.

Drugs & Aging, Vol. 16, Iss. 1, 2000-01 ,pp. : 9-27

Adis International

Access to resources Recommend Favorite

Fludarabine in chronic lymphocytic leukaemia

By Elter Thomas Hallek Michael Engert Andreas

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. : 1641-1651

Informa Healthcare

Access to resources Recommend Favorite

Chronic lymphocytic leukaemia

By Singer Charles Goldstone Tony

Clinical Medicine, Vol. 1, Iss. 5, 2001-09 ,pp. : 350-353

Royal College Of Physicians

Access to resources Recommend Favorite